| 09:00 - 09:10 |
Welcome and Introduction
Diabetes and Quality of Life
|
| 09:10 - 09:40 |
Importance of assessing quality of life to better guide
therapy for diabetes
A. Jacobson (US)
|
| 09:40 - 10:10 |
Influence of adherence to therapy, glycaemic control
and complications
F. Snoek (NL)
|
| 10:10 - 10:40 |
Which factors in diabetes mellitus affect quality of life
and how to translate these into clinical practice?
J. Johnson (CA)
|
| 10:40 - 11:10 |
Panel Discussion
|
| 11:10 - 11:40 |
Break
Diabetes and Therapeutic Choices
What is the glycaemic target?
And does it matter how we achieve it?
|
| 11:40 - 11:55 |
Introduction
|
| 11:55 - 12:30 |
Recent Trial data – Accord/VADT/ADVANCE, UKPDS Legacy
J. Skyler (US)
|
| 12:30 - 13:30 |
Lunch
|
| 13:30 - 14:00 |
How are the GLP-1 receptor agonists and
incretin-based treatments best utilised?
M. Diamant (NL)
|
| 14:00 - 14:30 |
Do the insulin kinetics matter in the treatment of T2DM?
How are they used in clinical practice and are they adequate?
G. Fulcher (AU)
|
| 14:30 - 15:00 |
Does the type of insulin used for treatment matter?
Lessons from recent RCTs
I. Raz (IL)
|
| 15:00 - 15:20 |
Panel Discussion
|
| 15:20 - 16:20 |
Debate: Proposition: Insulin Therapy in T2DM is the next step
for those failing Met and/or sulfonylurea therapy
A. Krentz (For) (UK)
S. Edelman (Against) (US)
|
| 16:20 - 16:30 |
Closing Remarks |
Symposia Programme
